Literature DB >> 9474361

General factors influencing drug delivery to the lung.

D Ganderton1.   

Abstract

The first devices to be developed for the delivery of bronchodilators and corticosteroids for the treatment of asthma were the pressurised metered dose inhalers (pMDIs). While pMDIs are viewed as patient friendly, they are associated with some serious disadvantages, such as considerable oropharyngeal deposition (due to the speed of delivery of the dose) and poor patient co-ordination of inhalation and activation. This has resulted in the development of alternative systems, such as the dry powder inhaler (DPI). However, DPIs also have problems, as there are difficulties in handling, measuring and metering fine particles. New devices, such as the Easi-breathe and Diskus inhalers, are now being introduced to overcome some of these problems. The ideal device is one that will produce a large proportion of respirable particles in the emitted dose. It must also deliver precise and uniform doses of drug to the patient. Further innovations are required to achieve these goals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9474361     DOI: 10.1016/s0954-6111(97)90099-8

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.

Authors:  Jagdeep Shur; Haggis Harris; Matthew D Jones; J Sebastian Kaerger; Robert Price
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

2.  The acoustic features of inhalation can be used to quantify aerosol delivery from a Diskus™ dry powder inhaler.

Authors:  Jansen N Seheult; Peter O'Connell; Kee Chun Tee; Tariq Bholah; Hasan Al Bannai; Imran Sulaiman; Elaine MacHale; Shona D'Arcy; Martin S Holmes; David Bergin; Emer Reeves; Richard B Reilly; Gloria Crispino-O'Connell; Carsten Ehrhardt; Anne Marie Healy; Richard W Costello
Journal:  Pharm Res       Date:  2014-05-28       Impact factor: 4.200

3.  Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI.

Authors:  Mariëlle E A C Broeders; Johan Molema; Wim C J Hop; Hans Th M Folgering
Journal:  Eur J Clin Pharmacol       Date:  2004-12-30       Impact factor: 2.953

4.  Investigating the relationship between peak inspiratory flow rate and volume of inhalation from a Diskus™ Inhaler and baseline spirometric parameters: a cross-sectional study.

Authors:  Jansen N Seheult; Simon Costello; Kee Chun Tee; Tariq Bholah; Hasan Al Bannai; Imran Sulaiman; Richard W Costello
Journal:  Springerplus       Date:  2014-09-02

5.  Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Authors:  David Prime; Wilfried de Backer; Melanie Hamilton; Anthony Cahn; Andrew Preece; Dennis Kelleher; Amanda Baines; Alison Moore; Noushin Brealey; Jackie Moynihan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-09-15       Impact factor: 2.849

6.  Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders.

Authors:  Richard N Dalby; Joachim Eicher; Bernd Zierenberg
Journal:  Med Devices (Auckl)       Date:  2011-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.